Cargando…
Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452617/ https://www.ncbi.nlm.nih.gov/pubmed/32885014 http://dx.doi.org/10.1016/j.gore.2020.100590 |
| _version_ | 1783575194947813376 |
|---|---|
| author | Santin, Alessandro D. Filiaci, Virginia Bellone, Stefania O'Cearbhaill, Roisin Ratner, Elena S. Mathews, Cara A. Cantuaria, Guilherme Gunderson, Camille C. Rutledge, Teresa Buttin, Barbara M. Lankes, Heather A. Birrer, Michael J. |
| author_facet | Santin, Alessandro D. Filiaci, Virginia Bellone, Stefania O'Cearbhaill, Roisin Ratner, Elena S. Mathews, Cara A. Cantuaria, Guilherme Gunderson, Camille C. Rutledge, Teresa Buttin, Barbara M. Lankes, Heather A. Birrer, Michael J. |
| author_sort | Santin, Alessandro D. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7452617 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74526172020-09-02 Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] Santin, Alessandro D. Filiaci, Virginia Bellone, Stefania O'Cearbhaill, Roisin Ratner, Elena S. Mathews, Cara A. Cantuaria, Guilherme Gunderson, Camille C. Rutledge, Teresa Buttin, Barbara M. Lankes, Heather A. Birrer, Michael J. Gynecol Oncol Rep Corrigendum Elsevier 2020-05-28 /pmc/articles/PMC7452617/ /pubmed/32885014 http://dx.doi.org/10.1016/j.gore.2020.100590 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Corrigendum Santin, Alessandro D. Filiaci, Virginia Bellone, Stefania O'Cearbhaill, Roisin Ratner, Elena S. Mathews, Cara A. Cantuaria, Guilherme Gunderson, Camille C. Rutledge, Teresa Buttin, Barbara M. Lankes, Heather A. Birrer, Michael J. Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] |
| title | Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] |
| title_full | Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] |
| title_fullStr | Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] |
| title_full_unstemmed | Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] |
| title_short | Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] |
| title_sort | corrigendum to “phase ii evaluation of copanlisib, a selective inhibitor of pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring pik3ca hotspot mutations: an nrg oncology study (nrg-gy008)” [gynecol. oncol. rep. 31 (2020) 100532] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452617/ https://www.ncbi.nlm.nih.gov/pubmed/32885014 http://dx.doi.org/10.1016/j.gore.2020.100590 |
| work_keys_str_mv | AT santinalessandrod corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT filiacivirginia corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT bellonestefania corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT ocearbhaillroisin corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT ratnerelenas corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT mathewscaraa corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT cantuariaguilherme corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT gundersoncamillec corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT rutledgeteresa corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT buttinbarbaram corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT lankesheathera corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 AT birrermichaelj corrigendumtophaseiievaluationofcopanlisibaselectiveinhibitorofpi3kcainpatientswithpersistentorrecurrentendometrialcarcinomaharboringpik3cahotspotmutationsannrgoncologystudynrggy008gynecoloncolrep312020100532 |